What is the appropriate antimicrobial coverage and dosing for methicillin‑sensitive Staphylococcus aureus (MSSA) infections (e.g., cellulitis), including IV and oral options, treatment duration, and alternatives for patients with penicillin allergy?

MSSA Coverage: Antimicrobial Selection and Dosing

For confirmed MSSA infections, use nafcillin or oxacillin (1-2 g IV every 4 hours) as first-line therapy, or cefazolin (1 g IV every 8 hours) for patients with non-severe penicillin allergy. 1

IV Therapy Options

First-Line Agents (Confirmed MSSA)

• Nafcillin or oxacillin: 1-2 g IV every 4 hours (adults); 100-150 mg/kg/day in 4 divided doses (children) 1

  • Parenteral drug of choice for MSSA
  • Inactive against MRSA

• Cefazolin: 1 g IV every 8 hours (adults); 50 mg/kg/day in 3 divided doses (children) 1

  • For penicillin-allergic patients except those with immediate hypersensitivity reactions
  • Recent evidence suggests comparable or superior outcomes to antistaphylococcal penicillins 2, 3, 4
  • Large retrospective cohort (7,312 episodes) showed no difference in 30-day mortality: cefazolin 10.7% vs flucloxacillin 11.2% 3

Alternative IV Agents

• Clindamycin: 600 mg IV every 8 hours (adults); 25-40 mg/kg/day in 3 divided doses (children) 1
  • Bacteriostatic
  • Risk of cross-resistance with erythromycin-resistant strains
  • Consider only if local clindamycin resistance rate <10%

Oral Therapy Options

First-Line Oral Agents (Confirmed MSSA)

• Dicloxacillin: 500 mg PO 4 times daily (adults); 25 mg/kg/day in 4 divided doses (children) 1

  • Oral agent of choice for methicillin-susceptible strains

• Cephalexin: 500 mg PO 4 times daily (adults); 25 mg/kg/day in 4 divided doses (children) 1

  • For penicillin-allergic patients except those with immediate hypersensitivity

Alternative Oral Agents

• Clindamycin: 300-450 mg PO 3 times daily (adults); 10-20 mg/kg/day in 3 divided doses (children) 1

• Doxycycline or minocycline: 100 mg PO twice daily (adults only) 1

  • NOT recommended for children <8 years of age 1
  • Bacteriostatic with limited recent clinical experience

• TMP-SMX: 1-2 double-strength tablets twice daily (adults); 8-12 mg/kg/day (based on trimethoprim) in 2-4 divided doses (children) 1

  • Bactericidal but efficacy poorly documented for MSSA

Treatment Duration by Clinical Syndrome

Skin and Soft Tissue Infections

• Outpatient cellulitis: 5-10 days, individualized based on clinical response 5, 6
• Hospitalized complicated SSTI: 7-14 days, individualized based on clinical response 5, 6
• Nonpurulent cellulitis: Empirical therapy should target β-hemolytic streptococci; cefazolin is appropriate for hospitalized patients 5

Bacteremia and Endocarditis

• Isolated tricuspid valve endocarditis (MSSA): ≤28 days with transition to oral therapy possible 7
  • Recent data shows 2.9% relapse rate with median 28 days treatment
  • 50% successfully transitioned to oral antibiotics for median 14 days
• General bacteremia: Duration depends on source control and metastatic complications 4

Penicillin Allergy Considerations

Critical caveat: Most patients reporting penicillin allergy are not truly allergic 8

Recommended Approach for Reported Penicillin Allergy:

1. Obtain detailed allergy history to exclude anaphylactic features
2. If history excludes anaphylaxis: Use cefazolin 8
3. If anaphylaxis history present: Consider penicillin skin testing
   • If skin test negative: Use cefazolin
   • If skin test positive or unavailable: Use vancomycin

Evidence: Decision analysis showed vancomycin results in lowest cure rates (67.3% vs 83.4% for cefazolin) and highest recurrence (14.8% vs 9.3%) in MSSA bacteremia with reported penicillin allergy 8

Special Populations

Pediatric Dosing

• Nafcillin/oxacillin: 100-150 mg/kg/day IV in 4 divided doses 1
• Cefazolin: 50 mg/kg/day IV in 3 divided doses 1
• Avoid tetracyclines in children <8 years 5, 6, 1

Hospitalized Patients with Nonpurulent Cellulitis

• β-lactam antibiotic (cefazolin) may be considered with modification to MRSA-active therapy if no clinical response 5
• This recognizes that β-hemolytic streptococci are the primary pathogen in nonpurulent cellulitis

Key Clinical Pitfalls

1. Avoid vancomycin for MSSA when β-lactams can be used—vancomycin has inferior outcomes 8, 4
2. Do not use rifampin as monotherapy or adjunctive therapy for SSTI 5
3. Cefazolin is NOT inferior to antistaphylococcal penicillins despite theoretical concerns about β-lactamase hydrolysis 2, 3
4. Most penicillin allergies are not true allergies—pursue allergy evaluation to optimize therapy 8
5. Source control is critical—remove infected devices, drain abscesses, debride as needed 4

Emerging Evidence

Recent data suggests penicillin-susceptible S. aureus (PSSA) accounts for 9% of MSSA SSTI in children and is independently associated with more severe disease requiring hospitalization and surgical intervention 9. While most labs don't routinely test for penicillin susceptibility in S. aureus, this phenotype may warrant consideration in select cases.